Effect of Specific Surface Area and Hydrophobicity of Electrospun Nanofibers on the Sustained Release Performance of Diclofenac Sodium
Source abstract
Abstract
Nanofibers produced by electrospinning are suitable options for slow-release materials. Diclofenac sodium (DS) is a nonsteroidal anti-inflammatory medication with a brief half-life that can serve as an effective sustained-release agent. This paper presents a novel method for producing DS-sustained release nanofibers by electrostatic spinning processes. During the preparation, the slow-release capabilities of biodegradable materials poly(lactic acid) (PLA) and polycaprolactone (PCL) are investigated. A composite drug-carrying scaffold is prepared to enhance the sustained-release performance. The sustained release ability is affected by the specific surface area of the nanofibers and the hydrophobicity of the polymer. The findings indicate that the composite nanofiber with a PLA/PCL ratio of 1:1 demonstrates the most effective sustained-release performance. The release rate is mostly influenced by the hydrophobicity of the polymer at this point. Sustained-release kinetic simulations were performed and revealed that the release of nanofibers follows a first-order release paradigm. This work presents a straightforward approach for creating a sustained-release formulation of DS.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Conducting polymers and applications · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Food and Chemical Engineering, Shaoyang University, Shaoyang 422000, China
Funding
Shaoyang University · Hunan Yuxin Pharmaceutical Co., Ltd · Shaoyang City Innovation Project
References (70)
Show source-provided references
1. 10.1096/fj.05-4434fje10.1096/fj.05-4434fje ↗
2. 10.2165/00003495-198020010-0000210.2165/00003495-198020010-00002 ↗
3. 10.1016/j.polymer.2022.12483610.1016/j.polymer.2022.124836 ↗
4. 10.1016/j.jddst.2022.10335310.1016/j.jddst.2022.103353 ↗
5. 10.1007/s12247-015-9227-410.1007/s12247-015-9227-4 ↗
6. 10.1016/j.ijpharm.2019.01.06410.1016/j.ijpharm.2019.01.064 ↗
7. 10.1016/j.ijpharm.2022.12227110.1016/j.ijpharm.2022.122271 ↗
8. 10.3109/10837450.2013.87103510.3109/10837450.2013.871035 ↗
9. 10.1080/10717544.2016.125600010.1080/10717544.2016.1256000 ↗
10. 10.1007/s10570-023-05070-610.1007/s10570-023-05070-6 ↗
11. 10.1016/j.porgcoat.2021.10657510.1016/j.porgcoat.2021.106575 ↗
12. 10.1021/acs.jafc.7b0121710.1021/acs.jafc.7b01217 ↗
13. 10.3389/fbioe.2022.104212810.3389/fbioe.2022.1042128 ↗
14. 10.1016/j.polymer.2009.07.00510.1016/j.polymer.2009.07.005 ↗
15. 10.1016/j.polymdegradstab.2008.08.00110.1016/j.polymdegradstab.2008.08.001 ↗
16. 10.1007/s10856-008-3622-z10.1007/s10856-008-3622-z ↗
17. 10.1016/j.polymer.2004.11.01310.1016/j.polymer.2004.11.013 ↗
18. 10.1016/j.biomaterials.2005.01.07110.1016/j.biomaterials.2005.01.071 ↗
19. 10.1016/j.eti.2021.10152810.1016/j.eti.2021.101528 ↗
20. 10.1002/mabi.20210004310.1002/mabi.202100043 ↗
21. 10.1016/j.ijpharm.2007.08.04610.1016/j.ijpharm.2007.08.046 ↗
22. 10.1002/app.5319910.1002/app.53199 ↗
23. 10.1002/ps.726410.1002/ps.7264 ↗
24. 10.1016/j.ijbiomac.2021.10.18110.1016/j.ijbiomac.2021.10.181 ↗
25. 10.3390/pharmaceutics1305074210.3390/pharmaceutics13050742 ↗
26. 10.1002/vnl.2190410.1002/vnl.21904 ↗
27. 10.1016/j.arabjc.2023.10494210.1016/j.arabjc.2023.104942 ↗
28. 10.1016/j.ijbiomac.2021.10.02710.1016/j.ijbiomac.2021.10.027 ↗
29. 10.1208/s12249-018-1261-310.1208/s12249-018-1261-3 ↗
30. 10.1080/24701556.2021.196328110.1080/24701556.2021.1963281 ↗
31. 10.1016/j.eurpolymj.2018.03.03210.1016/j.eurpolymj.2018.03.032 ↗
32. 10.1007/s13726-013-0145-310.1007/s13726-013-0145-3 ↗
33. 10.1016/j.ijbiomac.2019.02.11710.1016/j.ijbiomac.2019.02.117 ↗
34. 10.1016/j.jddst.2022.10338010.1016/j.jddst.2022.103380 ↗
35. Ghosal K. · Pharmazie · 2012 · 67 · 147
36. 10.1016/j.jcis.2021.02.09910.1016/j.jcis.2021.02.099 ↗
37. 10.3390/pharmaceutics1104018210.3390/pharmaceutics11040182 ↗
38. 10.1166/jnn.2021.1898710.1166/jnn.2021.18987 ↗
39. 10.1021/ma100423x10.1021/ma100423x ↗
40. 10.1007/s10973-021-11008-610.1007/s10973-021-11008-6 ↗
41. 10.1016/j.engfailanal.2016.06.00910.1016/j.engfailanal.2016.06.009 ↗
42. 10.1016/j.ijbiomac.2016.07.01310.1016/j.ijbiomac.2016.07.013 ↗
43. 10.1038/s41428-020-0308-y10.1038/s41428-020-0308-y ↗
44. 10.1080/10601325.2021.192159810.1080/10601325.2021.1921598 ↗
45. 10.3390/ma1520739610.3390/ma15207396 ↗
46. 10.3390/polym1010107310.3390/polym10101073 ↗
47. 10.1016/j.seppur.2020.11808110.1016/j.seppur.2020.118081 ↗
48. 10.1007/s10965-021-02439-810.1007/s10965-021-02439-8 ↗
49. 10.1016/j.eurpolymj.2017.09.01610.1016/j.eurpolymj.2017.09.016 ↗
50. 10.1002/pi.627310.1002/pi.6273 ↗
51. 10.1016/j.ijbiomac.2023.12627510.1016/j.ijbiomac.2023.126275 ↗
52. 10.1016/j.actbio.2021.07.01110.1016/j.actbio.2021.07.011 ↗
53. 10.1016/j.polymer.2017.12.02610.1016/j.polymer.2017.12.026 ↗
54. 10.1002/app.2891410.1002/app.28914 ↗
55. 10.1155/2022/519016310.1155/2022/5190163 ↗
56. 10.3390/polym1503055910.3390/polym15030559 ↗
57. 10.1016/j.polymertesting.2019.10632010.1016/j.polymertesting.2019.106320 ↗
58. 10.1016/j.polymdegradstab.2022.10986510.1016/j.polymdegradstab.2022.109865 ↗
59. 10.1016/j.molliq.2016.07.12710.1016/j.molliq.2016.07.127 ↗
60. 10.1007/s10924-019-01464-510.1007/s10924-019-01464-5 ↗
61. 10.1186/s40580-023-00366-610.1186/s40580-023-00366-6 ↗
62. 10.1007/s11244-022-01627-010.1007/s11244-022-01627-0 ↗
63. 10.5958/0974-360x.2019.00108.210.5958/0974-360x.2019.00108.2 ↗
64. 10.1016/j.jddst.2021.10249110.1016/j.jddst.2021.102491 ↗
65. 10.1016/j.ijbiomac.2019.09.05910.1016/j.ijbiomac.2019.09.059 ↗
66. 10.3390/polym1514299710.3390/polym15142997 ↗
67. 10.1016/j.ijbiomac.2022.07.19510.1016/j.ijbiomac.2022.07.195 ↗
68. 10.1080/00914037.2021.187605710.1080/00914037.2021.1876057 ↗
69. 10.1016/j.ejpb.2022.10.02310.1016/j.ejpb.2022.10.023 ↗
70. 10.1080/10667857.2019.165154910.1080/10667857.2019.1651549 ↗